Literature DB >> 31209398

Heart rate determines the beneficial effects of beta-blockers on cardiovascular outcomes in patients with heart failure and atrial fibrillation.

Athanasius Wrin Hudoyo1, Hiroki Fukuda1, Miki Imazu1, Kazuhiro Shindo1, Haiying Fu1, Yuko Iwata1, Shin Ito1, Masafumi Kitakaze2.   

Abstract

Beta-blockers are recommended as a standard therapy for patients with heart failure (HF). However, beta-blockers are reportedly less effective in HF patients with atrial fibrillation (Af) compared with those with sinus rhythm (SR). Here, we investigated whether HR at discharge determined the cardiovascular outcomes in HF patients with Af treated with beta-blockers. In this analysis, we enrolled 97 HF patients with concomitant Af. These patients were divided into 6 groups according to beta-blocker use and tertiles of discharge HR: lowest <60 beats per minute (bpm), middle 61-70 bpm and highest >71 bpm. The primary endpoint was defined as a composite of rehospitalization due to worsening of HF and all-cause mortality. During a median follow-up of 772 days after discharge, the composite cardiovascular outcome occurred in 37 (61%) and 25 (69%) patients with or without beta-blockers, respectively. In the Cox proportional hazard analysis, the lowest HR tertile in patients with beta-blockers was associated with an increased risk of the composite outcome compared with the middle and highest tertiles in both the unadjusted model (hazard ratio: 2.568, 95% confidence interval (CI): 1.089-6.057, p = 0.031; hazard ratio: 2.024, 95% CI: 0.921-4.447, p = 0.079, respectively) and the model adjusted for potential confounders (hazard ratio: 2.631, 95% CI: 1.078-6.421, p = 0.034; hazard ratio: 2.876, 95% CI: 1.147-7.207, p = 0.024, respectively). In patients with HF and Af receiving beta-blockers, low HR adversely increased the risk of cardiovascular events. This fact may blunt the beneficial effects of beta-blockers in patients with HF and Af.

Entities:  

Keywords:  atrial fibrillation; beta-blockers; heart failure; heart rate

Mesh:

Substances:

Year:  2019        PMID: 31209398     DOI: 10.1038/s41440-019-0289-4

Source DB:  PubMed          Journal:  Hypertens Res        ISSN: 0916-9636            Impact factor:   3.872


  33 in total

1.  Heart failure in patients with atrial fibrillation in Europe: a report from the EURObservational Research Programme Pilot survey on Atrial Fibrillation.

Authors:  Gregory Y H Lip; Cécile Laroche; Mircea I Popescu; Lars H Rasmussen; Laura Vitali-Serdoz; Gheorghe-Andrei Dan; Zbigniew Kalarus; Harry J G M Crijns; Mario M Oliveira; Luigi Tavazzi; Aldo P Maggioni; Giuseppe Boriani
Journal:  Eur J Heart Fail       Date:  2015-03-02       Impact factor: 15.534

2.  Atrial fibrillation: Challenging the status quo: β-blockers for HF plus AF.

Authors:  Paul Khairy; Denis Roy
Journal:  Nat Rev Cardiol       Date:  2014-10-14       Impact factor: 32.419

3.  A comparison of low versus high heart rate in patients with atrial fibrillation and advanced chronic heart failure: effects on clinical profile, neurohormones and survival.

Authors:  Michiel Rienstra; Isabelle C Van Gelder; Maarten P Van den Berg; Frans Boomsma; Hans L Hillege; Dirk J Van Veldhuisen
Journal:  Int J Cardiol       Date:  2005-07-01       Impact factor: 4.164

4.  Paroxysmal atrial fibrillation coincident with cardiac decompensation is a predictor of poor prognosis in chronic heart failure.

Authors:  Toshimi Koitabashi; Takayuki Inomata; Shinichi Niwano; Mototsugu Nishii; Ichiro Takeuchi; Hironari Nakano; Hisahito Shinagawa; Hitoshi Takehana; Tohru Izumi
Journal:  Circ J       Date:  2005-07       Impact factor: 2.993

Review 5.  Comorbidity of atrial fibrillation and heart failure.

Authors:  Liang-Han Ling; Peter M Kistler; Jonathan M Kalman; Richard J Schilling; Ross J Hunter
Journal:  Nat Rev Cardiol       Date:  2015-12-10       Impact factor: 32.419

Review 6.  Recent mortality and morbidity rates of Japanese atrial fibrillation patients: racial differences and risk stratification.

Authors:  Takeshi Yamashita
Journal:  Circ J       Date:  2013-03-01       Impact factor: 2.993

7.  Temporal relations of atrial fibrillation and congestive heart failure and their joint influence on mortality: the Framingham Heart Study.

Authors:  Thomas J Wang; Martin G Larson; Daniel Levy; Ramachandran S Vasan; Eric P Leip; Philip A Wolf; Ralph B D'Agostino; Joanne M Murabito; William B Kannel; Emelia J Benjamin
Journal:  Circulation       Date:  2003-05-27       Impact factor: 29.690

8.  Effects of atrial fibrillation on long-term outcomes in patients hospitalized for heart failure in Japan: a report from the Japanese Cardiac Registry of Heart Failure in Cardiology (JCARE-CARD).

Authors:  Sanae Hamaguchi; Hisashi Yokoshiki; Shintaro Kinugawa; Miyuki Tsuchihashi-Makaya; Takashi Yokota; Akira Takeshita; Hiroyuki Tsutsui
Journal:  Circ J       Date:  2009-09-15       Impact factor: 2.993

9.  Efficacy of β blockers in patients with heart failure plus atrial fibrillation: an individual-patient data meta-analysis.

Authors:  Dipak Kotecha; Jane Holmes; Henry Krum; Douglas G Altman; Luis Manzano; John G F Cleland; Gregory Y H Lip; Andrew J S Coats; Bert Andersson; Paulus Kirchhof; Thomas G von Lueder; Hans Wedel; Giuseppe Rosano; Marcelo C Shibata; Alan Rigby; Marcus D Flather
Journal:  Lancet       Date:  2014-09-02       Impact factor: 79.321

Review 10.  Heart Rate and Rhythm and the Benefit of Beta-Blockers in Patients With Heart Failure.

Authors:  Dipak Kotecha; Marcus D Flather; Douglas G Altman; Jane Holmes; Giuseppe Rosano; John Wikstrand; Milton Packer; Andrew J S Coats; Luis Manzano; Michael Böhm; Dirk J van Veldhuisen; Bert Andersson; Hans Wedel; Thomas G von Lueder; Alan S Rigby; Åke Hjalmarson; John Kjekshus; John G F Cleland
Journal:  J Am Coll Cardiol       Date:  2017-04-30       Impact factor: 24.094

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.